An investigational transcatheter mitral valve replacement (TMVR) device helped reduce mitral regurgitation to zero or trace levels in 98.7 percent of patients, according to 30-day follow-up data from the first 100 people scheduled to be treated with Abbott’s Tendyne system.

DUBLIN and PARIS — May 24, 2018 — Investigators today unveiled clinical data from the independently run Onyx 1-Month OCT Study, which showed strong early vessel healing in a patient population that contained a high percentage of patients with complex coronary artery disease who were implanted with the Resolute Onyx(TM) DES at one-month follow-up.

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

A randomized trial published April 24 in JAMA suggests patients with lower-extremity peripheral artery disease (PAD) can’t be expected to improve walking performance on their own, even with the aid of wearable activity trackers and telephone coaching sessions.

Cocaine addiction can ruin a person physically and financially, and with an estimated 1.4 million cocaine users in the U.S., thousands will become trapped by their habit. While previous research on the drug and its addictive potential were observational and subjective, imaging is reshaping how we see addiction—and how it will be treated.

PET with 11C-PIB provides a noninvasive method for visualizing amyloid deposits in the heart, according to a study published in the February issue of the Journal of Nuclear Medicine. The researchers suggest that 11C-PIB eventually may be used in the clinical setting as both a diagnostic tool and a treatment follow-up method.